Long-Term Follow-Up Studies: Gene Therapy Products, Protocols And Potential Issues
By Meredith Latino
![GettyImages-970394878-genetic-engineering-gene-editing-dna GettyImages-970394878-genetic-engineering-gene-editing-dna](https://vertassets.blob.core.windows.net/image/02146912/02146912-5210-44dc-888c-ac879c6f93d8/375_250-gettyimages_970394878_genetic_engineering_gene_editing_dna.jpg)
A “long-term” study is one that gathers data on research subjects for 5 years or more. Long-term follow‑up observations are extended assessments that continue some of the scheduled observations of a clinical trial past the active follow-up period.1
There are several arguments for conducting studies to assessing the long-term risk of drugs. The information gained from this research can play an important role in health promotion and disease prevention. Regulatory authorities can use data from long-term drug studies to require changes in labeling or medication guidance, or even withdraw a drug. Physicians and patients can use the data from long-term studies to make decisions related to treatment or prevention. In addition, long-term studies are needed for monitoring effectiveness and long-term safety, particularly for studies in patients who require chronic treatment for their disease.2 Information provided by long-term clinical studies complements the results of short-term, randomized, controlled trials, which often form the basis of regulatory approval for a new drug application.3
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.